Neurogene (NGNE) Interest Coverage Ratio (2013 - 2026)
Neurogene's (NGNE) quarterly Interest Coverage Ratio came in at 4.63 in Q1 2026, up 87.49% YoY from 2.47 in Q1 2025, and up 96.2% on a QoQ basis from 121.81 in Q4 2025.
Neurogene (NGNE) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 13 years of Interest Coverage Ratio data on file, last reported at 4.63 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 87.49% year-over-year to 4.63 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.38 (up 88.0% YoY) and the FY2025 annual result came in at 0.74, down 2.89% from the prior year.
- Interest Coverage Ratio climbed to 4.63 in Q1 2026, from 121.81 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.31 in Q4 2022 to a low of 10756.0 in Q4 2024.
- A 5-year average of 1272.39 and a median of 121.81 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio slumped 253488.13% — and 2024, when it soared 99.99%.
- Tracing NGNE's Interest Coverage Ratio over 5 years: stood at 0.31 in 2022, then tumbled by 253488.13% to 775.42 in 2023, then tumbled by 1287.12% to 10756.0 in 2024, then soared by 98.87% to 121.81 in 2025, then surged by 96.2% to 4.63 in 2026.
- The last three Interest Coverage Ratio figures came in at 4.63 (Q1 2026), 121.81 (Q4 2025), and 8.21 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | -1.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.18 |
| Mar 31, 2026 | -4.63 |
| Dec 31, 2025 | -121.81 |
| Sep 30, 2025 | -8.21 |
| Jun 30, 2025 | -17.39 |
| Mar 31, 2025 | -37.03 |
| Dec 31, 2024 | -10,756.00 |
| Sep 30, 2024 | -1.11 |
| Jun 30, 2024 | -1.49 |
| Mar 31, 2024 | -0.58 |
| Dec 31, 2023 | -775.42 |
| Sep 30, 2023 | -3,804.75 |
| Jun 30, 2023 | -839.73 |
| Mar 31, 2023 | -4,345.00 |
| Dec 31, 2022 | -0.31 |
| Sep 30, 2022 | -147.92 |
| Jun 30, 2022 | -220.43 |
| Mar 31, 2022 | -548.75 |
| Dec 31, 2021 | -0.60 |
| Sep 30, 2021 | -0.84 |